Rahul Gupta authored this article.

Emerging and growth-stage pharma companies rarely underperform because of weak science. More often, they fall short because they wait too long to think like franchise builders.

The commercialization environment has shifted. Launch density is rising. Payer scrutiny is intensifying. Adoption curves in many specialty categories are flattening. ZS analysis shows that only about 60% of recent biopharma launches met or beat initial peak revenue expectations, even with strong clinical profiles. Time to peak revenue has also lengthened across multiple therapeutic areas, ZS research finds.

In this context, regulatory approval is no longer the defining milestone of success. It’s the starting point.

Yet many organizations remain asset-centric—focused on advancing trials, achieving approval and assembling launch capabilities in the final 12-18 months before commercialization. Evidence generation is optimized for regulatory endpoints rather than long-term access durability. Infrastructure is built for a single product, not a scalable portfolio. That model no longer holds.

The companies that outperform shift from asset thinking to portfolio thinking well before approval.

Shifting pharma commercialization strategy from asset thinking versus portfolio thinking

Asset-centric thinking is linear and milestone-driven. It optimizes for approval. Portfolio thinking is systemic and value-driven. It optimizes for durability.

Instead of asking, “How do we get this product approved?” portfolio-oriented leaders ask:

• How defensible will this asset be in a constrained pricing environment?
• What evidence will payers require over the life cycle—not just at launch?
• How should commercial capabilities scale when additional assets reach the market? How do I build my organization around it?
• What decisions today will compound enterprise value tomorrow?

This shift changes investment timing, governance and organizational design. ZS research shows that high-performing launches integrate commercial access and evidence-planning years before approval, rather than sequencing them afterward.

The phase 2 inflection point in pharma launch strategy

The most underleveraged strategic window, especially in emerging and growth-stage pharma, is the transition from phase 2 to early phase 3.

At this stage, clinical signal clarity improves and competitive positioning sharpens, but trial design and evidence strategy are still influenceable. It’s often the last opportunity to align development with commercial reality.

Payer expectations increasingly extend beyond efficacy and safety to comparative value, health economic endpoints and real-world evidence. Companies that embed commercial and access insight into phase 3 design reduce post-approval friction. Those that do not frequently retrofit evidence after launch, a slower and more expensive path.

The impact is durable. ZS research indicates that revenue lost in the first 12-24 months due to suboptimal launch execution is hardly ever fully recovered over the product life cycle. Early access constraints can permanently compress peak potential. ZS research finds that for about 60% of launched products, analysts have lowered their launch year+1 year’s estimates by an average of ~40% of sale. The launch year+2 year estimates were slashed by ~60% for ~80% of products.

Leadership timing is critical here. Organizations that embed commercial expertise into governance before phase 3 are better positioned to shape pricing architecture, evidence strategy and capability design while decisions remain influenceable. Delaying that integration may conserve capital in the short term, but it often narrows the long-term upside.

Precision over scale in go-to-market design to improve launch success

Long-term portfolio thinking also reshapes go-to-market strategy.

Traditional field-heavy models are no longer sufficient. Engagement must be orchestrated, sequenced and data-informed. Investment in AI and digital enablement drives results only when anchored to clearly defined customer needs and well-designed journeys. Increasingly, that includes agentic AI: governed, goal-driven decision systems that sense, decide, act and learn across the commercial value stream under guardrails and human oversight, not just smarter tools.

High-performing launches integrate:

• Coordinated field and digital engagement
• Data-driven segmentation
• Clearly defined customer journeys
• Predictive analytics to guide deployment
  
  These capabilities can be supported by an agentic AI system that runs a continuous sense, decide, act and learn loop on engagement decisions within compliance/access guardrails.

For emerging companies competing against larger organizations, precision becomes a strategic advantage. Optimizing deployment, channel mix and sequencing enables impact without matching share of voice (which is often cost prohibitive).

Equally important is scalability. Companies that build one-off forecasting, analytics and data systems for a single launch often face costly rebuilds as pipelines expand. Early investment in modular infrastructure compounds advantage across assets.

From pharma launch event to durable franchise

When commercialization is treated as an endpoint, predictable performance gaps follow: slower adoption, pricing pressure and limited scalability. Over time, those gaps compound.

Emerging and growth-stage pharma companies that build enduring franchises do three things differently:

1. They integrate commercial strategy into clinical decision-making early
2. They design infrastructure to scale beyond a single asset
3. They treat the launch as the beginning of an iterative growth model, not a one-time event

Agentic AI helps convert each launch into a learning system for the portfolio, capturing signals, updating assumptions and informing future decisions across the portfolio.

Science creates possibility. Portfolio strategy converts possibility into durable enterprise value. For leaders in emerging and growth-stage pharma, the question is no longer whether commercialization matters. It is when to elevate it to strategic parity with development.

Increasingly, the answer is phase 2.

Keep exploring emerging and growth stage biotech insights here.